CZ298110B6 - Lyofilizovaná, ve spreji susená nebo vakuove susená farmaceutická kompozice a zpusob její výroby - Google Patents

Lyofilizovaná, ve spreji susená nebo vakuove susená farmaceutická kompozice a zpusob její výroby Download PDF

Info

Publication number
CZ298110B6
CZ298110B6 CZ20000083A CZ200083A CZ298110B6 CZ 298110 B6 CZ298110 B6 CZ 298110B6 CZ 20000083 A CZ20000083 A CZ 20000083A CZ 200083 A CZ200083 A CZ 200083A CZ 298110 B6 CZ298110 B6 CZ 298110B6
Authority
CZ
Czechia
Prior art keywords
pharmaceutical composition
composition according
compound
dried
drying
Prior art date
Application number
CZ20000083A
Other languages
Czech (cs)
English (en)
Other versions
CZ200083A3 (cs
Inventor
Broadhead@Joanne
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ298110(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of CZ200083A3 publication Critical patent/CZ200083A3/cs
Publication of CZ298110B6 publication Critical patent/CZ298110B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CZ20000083A 1997-07-11 1998-06-29 Lyofilizovaná, ve spreji susená nebo vakuove susená farmaceutická kompozice a zpusob její výroby CZ298110B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation

Publications (2)

Publication Number Publication Date
CZ200083A3 CZ200083A3 (cs) 2000-06-14
CZ298110B6 true CZ298110B6 (cs) 2007-06-27

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20000083A CZ298110B6 (cs) 1997-07-11 1998-06-29 Lyofilizovaná, ve spreji susená nebo vakuove susená farmaceutická kompozice a zpusob její výroby

Country Status (35)

Country Link
US (1) US6130208A (cg-RX-API-DMAC10.html)
EP (1) EP1000079B1 (cg-RX-API-DMAC10.html)
JP (1) JP4950380B2 (cg-RX-API-DMAC10.html)
KR (1) KR100786654B1 (cg-RX-API-DMAC10.html)
CN (2) CN1864696A (cg-RX-API-DMAC10.html)
AR (1) AR013157A1 (cg-RX-API-DMAC10.html)
AT (1) ATE340801T1 (cg-RX-API-DMAC10.html)
AU (1) AU8362598A (cg-RX-API-DMAC10.html)
BR (1) BR9810703A (cg-RX-API-DMAC10.html)
CA (1) CA2295628C (cg-RX-API-DMAC10.html)
CY (1) CY1105805T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ298110B6 (cg-RX-API-DMAC10.html)
DE (1) DE69836023T2 (cg-RX-API-DMAC10.html)
DK (1) DK1000079T3 (cg-RX-API-DMAC10.html)
EE (1) EE04119B1 (cg-RX-API-DMAC10.html)
ES (1) ES2273425T3 (cg-RX-API-DMAC10.html)
HU (1) HU226489B1 (cg-RX-API-DMAC10.html)
ID (1) ID24716A (cg-RX-API-DMAC10.html)
IL (2) IL133868A0 (cg-RX-API-DMAC10.html)
IS (1) IS2439B (cg-RX-API-DMAC10.html)
MY (1) MY116421A (cg-RX-API-DMAC10.html)
NO (1) NO329918B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ502073A (cg-RX-API-DMAC10.html)
PL (1) PL192768B1 (cg-RX-API-DMAC10.html)
PT (1) PT1000079E (cg-RX-API-DMAC10.html)
RU (1) RU2216330C2 (cg-RX-API-DMAC10.html)
SA (1) SA98190328B1 (cg-RX-API-DMAC10.html)
SE (1) SE9702680D0 (cg-RX-API-DMAC10.html)
SI (1) SI1000079T1 (cg-RX-API-DMAC10.html)
SK (1) SK285766B6 (cg-RX-API-DMAC10.html)
TR (1) TR200000006T2 (cg-RX-API-DMAC10.html)
TW (1) TW585764B (cg-RX-API-DMAC10.html)
UA (1) UA65576C2 (cg-RX-API-DMAC10.html)
WO (1) WO1999002542A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA985669B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038647A1 (ja) * 2004-10-05 2006-04-13 Asahi Kasei Pharma Corporation 補酵素の安定化方法およびその組成物
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
JP5597202B2 (ja) 2009-08-28 2014-10-01 第一三共株式会社 ３−（ビアリールオキシ）プロピオン酸誘導体
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2498731B1 (en) 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
WO2012079035A1 (en) * 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
DK2744424T3 (en) 2011-08-17 2018-01-22 Samuel Shiber Adaptively rotating catheter to open clogged vessels in the body
EP3978002A1 (en) 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
PE20221170A1 (es) 2015-01-14 2022-07-25 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
ES3067885T3 (en) 2017-06-23 2026-05-26 Chiesi Farm Spa Cangrelor for the treatment and/or prevention of shunt or stent thrombosis
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423811A1 (de) * 1973-05-17 1974-12-05 Kohjin Co Verfahren zur herstellung von gefriergetrockneten 2,2'-anhydro-1-beta-d-arabinofuranosylcytosin-praeparaten und injektionspraeparat
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
WO1994018216A1 (en) * 1993-02-10 1994-08-18 Astra Pharmaceuticals Limited N-alkyl-2-substituted atp analogues
EP0658348A2 (en) * 1993-12-14 1995-06-21 Eli Lilly And Company Aqueous solution inclusion complexes of benzothiophene compounds with cyclodextrins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
WO1996040265A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423811A1 (de) * 1973-05-17 1974-12-05 Kohjin Co Verfahren zur herstellung von gefriergetrockneten 2,2'-anhydro-1-beta-d-arabinofuranosylcytosin-praeparaten und injektionspraeparat
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
WO1994018216A1 (en) * 1993-02-10 1994-08-18 Astra Pharmaceuticals Limited N-alkyl-2-substituted atp analogues
EP0658348A2 (en) * 1993-12-14 1995-06-21 Eli Lilly And Company Aqueous solution inclusion complexes of benzothiophene compounds with cyclodextrins

Also Published As

Publication number Publication date
DK1000079T3 (da) 2006-11-20
SE9702680D0 (sv) 1997-07-11
TR200000006T2 (tr) 2000-07-21
CA2295628C (en) 2008-07-29
DE69836023T2 (de) 2007-04-12
SK285766B6 (sk) 2007-07-06
UA65576C2 (uk) 2004-04-15
ATE340801T1 (de) 2006-10-15
CZ200083A3 (cs) 2000-06-14
HK1026429A1 (en) 2000-12-15
AR013157A1 (es) 2000-12-13
HUP0002622A3 (en) 2002-04-29
EE200000022A (et) 2000-10-16
IS5331A (is) 1999-12-30
KR100786654B1 (ko) 2007-12-21
TW585764B (en) 2004-05-01
IL133868A (en) 2010-05-17
RU2216330C2 (ru) 2003-11-20
KR20010021647A (ko) 2001-03-15
EP1000079B1 (en) 2006-09-27
WO1999002542A1 (en) 1999-01-21
EE04119B1 (et) 2003-08-15
AU8362598A (en) 1999-02-08
PL192768B1 (pl) 2006-12-29
CA2295628A1 (en) 1999-01-21
US6130208A (en) 2000-10-10
SK183699A3 (en) 2000-07-11
EP1000079A1 (en) 2000-05-17
IL133868A0 (en) 2001-04-30
NZ502073A (en) 2001-09-28
MY116421A (en) 2004-01-31
CN1263533A (zh) 2000-08-16
CY1105805T1 (el) 2011-02-02
SA98190328B1 (ar) 2006-08-15
PL337970A1 (en) 2000-09-11
NO20000123L (no) 2000-03-03
BR9810703A (pt) 2000-08-08
HU226489B1 (en) 2009-03-02
JP4950380B2 (ja) 2012-06-13
NO329918B1 (no) 2011-01-24
ES2273425T3 (es) 2007-05-01
JP2001509512A (ja) 2001-07-24
ID24716A (id) 2000-08-03
NO20000123D0 (no) 2000-01-10
CN1864696A (zh) 2006-11-22
ZA985669B (en) 1999-01-11
HUP0002622A2 (hu) 2001-05-28
DE69836023D1 (de) 2006-11-09
PT1000079E (pt) 2006-12-29
SI1000079T1 (sl) 2007-08-31
IS2439B (is) 2008-11-15

Similar Documents

Publication Publication Date Title
JP4950380B2 (ja) 新規な製剤
JP3083156B2 (ja) Ｎ−アルキル−２−置換ａｔｐ類似体
JP5227029B2 (ja) デシタビン医薬製剤
US5942510A (en) Pharmaceutical composition containing lamotrigine
RU2205012C2 (ru) Фармацевтические композиции для сушки вымораживанием
US20040198652A1 (en) Methods and compositions for preventing and treating septic shock and endotoxemia
CZ271894A3 (en) Lyophilized preparation containing 1,1,1-phosphinothioylidintrisaziridine and process for preparing thereof
AU2003257524B2 (en) New formulation
HK1026429B (en) New formulation
MXPA00000100A (en) New formulation
CZ280278B6 (cs) Způsob výroby lyofilizovaného preparátu 6-(3-dimethylaminopropio nyl)forskolinu
HK1026366B (en) Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying
MXPA99005664A (en) Pharmaceutical compositions for freeze drying

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20080629